Hide metadata

dc.date.accessioned2018-09-12T14:00:45Z
dc.date.available2018-09-12T14:00:45Z
dc.date.created2017-11-07T14:58:19Z
dc.date.issued2017
dc.identifier.citationGarcia Lopez, Maria Bønaa, Kaare Ebbing, Marta Eriksen, Erik Fink Gjesdal, Clara Gram Nygård, Ottar Tell, Grethe S. Ueland, Per Magne Meyer, Haakon E . B Vitamins and Hip Fracture: Secondary Analyses and Extended Follow-Up of Two Large Randomized Controlled Trials. Journal of Bone and Mineral Research. 2017, 32(10), 1981-1989
dc.identifier.urihttp://hdl.handle.net/10852/64679
dc.description.abstractElevated plasma homocysteine levels are associated with increased risk of fractures in observational studies. However, it is unsettled whether homocysteine‐lowering treatment affects fracture risk. The aim of this study was to investigate the effect of an intervention with B vitamins on the risk of hip fracture in a secondary analysis of combined data from two large randomized controlled trials originally designed to study cardiovascular diseases. Both trials had identical design, intervention, and primary objective. Based on a two‐by‐two factorial design, the intervention consisted of a daily capsule with either (1) folic acid (0.8 mg) plus vitamin B12 (0.4 mg) and vitamin B6 (40 mg); (2) folic acid (0.8 mg) plus vitamin B12 (0.4 mg); (3) vitamin B6 alone (40 mg); or (4) placebo. The participants were followed with respect to hip fracture during the trial or during an extended follow‐up (from the trial start for each patient until the end of 2012). No statistically significant association was found between folic acid plus vitamin B12 treatment and the risk of hip fracture, neither during the trial (median 3.3 years; hazard ratio [HR] 0.87; 95% confidence interval [CI], 0.48 to 1.59) nor during the extended follow‐up (median 11.1 years; HR 1.08; 95% CI, 0.84 to 1.40). Nor were there significant differences in the risk of hip fracture between groups receiving versus not receiving vitamin B6 during the trial (HR 1.42; 95% CI, 0.78 to 2.61). However, during the extended follow‐up, those receiving vitamin B6 showed a significant 42% higher risk of hip fracture (HR 1.42; 95% CI, 1.09 to 1.83) compared to those not receiving vitamin B6. In conclusion, treatment with folic acid plus vitamin B12 was not associated with the risk of hip fracture. Treatment with a high dose of vitamin B6 was associated with a slightly increased risk of hip fracture during the extended follow‐up (in‐trial plus post‐trial follow‐up). © 2017 American Society for Bone and Mineral Research.en_US
dc.languageEN
dc.language.isoenen_US
dc.publisherMary Ann Liebert, Inc.
dc.titleB Vitamins and Hip Fracture: Secondary Analyses and Extended Follow-Up of Two Large Randomized Controlled Trialsen_US
dc.typeJournal articleen_US
dc.creator.authorGarcia Lopez, Maria
dc.creator.authorBønaa, Kaare
dc.creator.authorEbbing, Marta
dc.creator.authorEriksen, Erik Fink
dc.creator.authorGjesdal, Clara Gram
dc.creator.authorNygård, Ottar
dc.creator.authorTell, Grethe S.
dc.creator.authorUeland, Per Magne
dc.creator.authorMeyer, Haakon E
cristin.unitcode185,52,14,0
cristin.unitnameAvdeling for samfunnsmedisin og global helse
cristin.ispublishedtrue
cristin.fulltextpreprint
cristin.qualitycode2
dc.identifier.cristin1511867
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal of Bone and Mineral Research&rft.volume=32&rft.spage=1981&rft.date=2017
dc.identifier.jtitleJournal of Bone and Mineral Research
dc.identifier.volume32
dc.identifier.issue10
dc.identifier.startpage1981
dc.identifier.endpage1989
dc.identifier.doihttp://dx.doi.org/10.1002/jbmr.3189
dc.identifier.urnURN:NBN:no-67228
dc.type.documentTidsskriftartikkelen_US
dc.source.issn0884-0431
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/64679/4/Lopez%2Bet%2Bal%2BJBMR%2B2017.pdf
dc.type.versionSubmittedVersion


Files in this item

Appears in the following Collection

Hide metadata